Weekly paclitaxel and trastuzumab as a first-line therapy in patients with HER2-overexpressing metastatic breast cancer: magnitude of HER2/neu amplification as a predictive factor for efficacy.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples